Diagnosis of Contagious Bovine Pleuropneumonia: overview and gap analysis

Manso-Silvan Lucia. 2024. Diagnosis of Contagious Bovine Pleuropneumonia: overview and gap analysis. . s.l. : Enhancing Research For Africa Network, 1 p. CBPP Online Fora, Forum 5: Diagnosis of Contagious Bovine Pleuropneumonia, s.l., 24 Février 2024/24 Février 2024.

Matériel d'accompagnement : 1 diaporama (33 vues)

Résumé : CBPP is a severe respiratory disease of cattle, caused by the bacterium Mycoplasma mycoides subsp. mycoides (Mmm). The disease is endemic in most of Sub-Saharan Africa, where it inflicts severe losses, posing a threat to food security and compromising peoples' livelihoods and wellbeing. Since CBPP lesions are highly evocative, abattoir surveillance and post-mortem investigations of lung lesions are of paramount importance for diagnosis and constitute the basis for disease surveillance in CBPP-free countries. Molecular diagnostic assays (conventional and real-time, quantitative PCR tests) may be used for the rapid confirmation of CBPP suspicions, while serology is used for animal testing before trade. In endemic regions, clinical and abattoir investigations are rarely conducted, the isolation and molecular detection of the CBPP agent are even more infrequently performed, and the disease is hardly ever reported. Both the complement fixation test (CFT) and competition ELISA (cELISA) are used for surveillance and prevalence studies, though due to their limited sensitivity they can only be interpreted at herd level and the availability of commercial products is currently an important issue. Inexpensive tests, easy to operate at the pen-side are needed for disease confirmation in remote regions, far from diagnostic laboratories. Research is needed to develop more effective tools and strategies for the control of the disease. Extensive comparative “omics” analyses conducted on a large sample of strains representing the temporal and spatial diversity of Mmm and other members of the “Mycoplasma mycoides” cluster are needed to determine representative pan and core genomes at different levels. These will facilitate the development of diagnostic and genotyping tools, as well as the identification of the molecular basis of virulence, attenuation, and acquisition of AMR. Market studies are also needed to assess the demand and affordability of new diagnostics and the involvement of manufacturing companies is required to target and optimise the development of inventions into successful commercial products. Serological and direct molecular assays must be validated by international standards and inter-laboratory assays, and reference materials and qualified sample panels are needed for these validations.

Mots-clés libres : CBPP, Diagnostics, Serology, Molecular diagnosis

Auteurs et affiliations

• Manso-Silvan Lucia, CIRAD-BIOS-UMR ASTRE (FRA) ORCID: 0000-0002-5539-3804

Source : Cirad-Agritrop (https://agritrop.cirad.fr/608798/)

Métriques

[ Page générée et mise en cache le 2024-03-14 ]